2023年8月8日 · Complement factor H (CFH) negatively regulates consumption of complement component 3 (C3), thereby restricting complement activation. Genetic variants in CFH predispose to chronic inflammatory disease. Here, we examined the impact of …

补体因子 h (cfh) 负向调节补体成分 3 (c3) 的消耗，从而限制补体激活。 CFH的基因变异易患慢性炎症性疾病。 在这里，我们研究了 CFH 对动脉粥样硬化发展的影响。

C3 glomerulopathy is characterized by accumulation of complement C3 within glomeruli. Causes include, but are not limited to, abnormalities in factor H, the major negative regulator of the complement alternative pathway. Factor H-deficient (Cfh-/-) mice develop C3

2023年8月8日 · Complement factor H (CFH) negatively regulates consumption of complement component 3 (C3), thereby restricting complement activation. Genetic variants in CFH predispose to chronic inflammatory disease. Here, we examined the impact of …

Complement factor H (CFH) negatively regulates consumption of complement component 3 (C3), thereby re-stricting complement activation. Genetic variants in predispose to chronic inflammatory disease. Here, we examined the impact of CFH on atherosclerosis development.

2016年1月15日 · Here we report that FH is actively internalized by apoptotic cells to enhance cathepsin L-mediated cleavage of endogenously expressed C3, which results in increased surface opsonization with iC3b.

3 天之前 · Notably, C3 co-expressed with Factor H (FH) in human and mouse myeloid cells in atherosclerotic lesions is readily detected, and deletion of Cfh/CFH from such cells depletes the intracellular C3 pool, suggesting that intracellular FH restrains processing of C3 and prevents its exhaustion44, a hypothesis that awaits experimental confirmation.

2025年1月1日 · This study identifies CFH as a central regulator in IPF, linking complement dysregulation to macrophage dysfunction and fibrotic progression. CFH promotes fibrosis by suppressing macrophage efferocytosis and autophagy through autocrine C3 regulation, creating a pro-fibrotic microenvironment.

2022年4月1日 · In this study, we investigated the effects of N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) targeting the C3 component of complement that inhibits liver C3 expression in the C3G model of mice with heterozygous deficiency of …

AMD is associated with genetic variation in complement proteins that results in enhanced activation of C3 through the complement alternative pathway. These include complement factor H (CFH), a negative regulator of C3 activation. Both C3 inhibition and/or CFH augmentation are potential therapeutic strategies in AMD.